Table 4.

Effectiveness of apremilast on mucocutaneous manifestations.

	M3	M6	EOF
Oral ulcers
n	41	33	28
Complete response, n (%)	26 (63)	24 (73)	15 (54)
Partial response, n (%)	12 (29)	8 (24)	6 (21)
Genital ulcers
n	20	17	15
Complete response, n (%)	15 (75)	16 (94)	11 (73)
Partial response, n (%)	3 (15)	1 (6)	1 (7)
Pseudofolliculitis
n	16	14	11
Complete response, n (%)	11 (69)	10 (71)	7 (64)
Partial response, n (%)	4 (31)	4 (29)	4 (36)
Erythema nodosum
n	4	2	2
Complete response, n (%)	3 (75)	1 (50)	1 (50)
Partial response, n (%)	0	1 (50)	0

EOF, end of follow-up.